Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355238 · ClinicalTrials.gov registry record · Phase 2
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00355238 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 137 participants.
The verdict
NCT00355238, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.
Interventions
- DRUG brivanib (active)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2006-12-31 |
| Est. Completion | 2010-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00355238
The ClinicalTrials.gov registry entry for NCT00355238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which brivanib (active) is the first listed.
NCT00355238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00355238 about?
NCT00355238 is a clinical study titled "A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer". The purpose of this clinical research study is to learn if BMS-582664 can shrink or slow the growth of advanced liver cancer. The safety of this treatment will also be studied.
What is the current status of trial NCT00355238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2006-12-31. Estimated completion is 2010-04-30.
What interventions are being tested in trial NCT00355238?
The interventions under investigation include: brivanib (active) (DRUG).
Who is sponsoring clinical trial NCT00355238?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.